These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20843337)

  • 1. Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.
    De Lisle RC; Mueller R; Roach E
    BMC Gastroenterol; 2010 Sep; 10():107. PubMed ID: 20843337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of small intestinal bacterial overgrowth in the cystic fibrosis mouse reduces mucus accumulation.
    De Lisle RC; Roach EA; Norkina O
    J Pediatr Gastroenterol Nutr; 2006 Jan; 42(1):46-52. PubMed ID: 16385253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine.
    De Lisle RC; Roach E; Jansson K
    Am J Physiol Gastrointest Liver Physiol; 2007 Sep; 293(3):G577-84. PubMed ID: 17615175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mast cells and gastrointestinal dysmotility in the cystic fibrosis mouse.
    De Lisle RC; Meldi L; Roach E; Flynn M; Sewell R
    PLoS One; 2009; 4(1):e4283. PubMed ID: 19172182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine.
    Norkina O; Burnett TG; De Lisle RC
    Infect Immun; 2004 Oct; 72(10):6040-9. PubMed ID: 15385508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator.
    Bijvelds MJ; Bot AG; Escher JC; De Jonge HR
    Gastroenterology; 2009 Sep; 137(3):976-85. PubMed ID: 19454284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome.
    Bazett M; Honeyman L; Stefanov AN; Pope CE; Hoffman LR; Haston CK
    Mamm Genome; 2015 Jun; 26(5-6):222-34. PubMed ID: 25721416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired mucosal barrier function in the small intestine of the cystic fibrosis mouse.
    De Lisle RC; Mueller R; Boyd M
    J Pediatr Gastroenterol Nutr; 2011 Oct; 53(4):371-9. PubMed ID: 21970994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine.
    De Lisle RC
    Am J Physiol Gastrointest Liver Physiol; 2007 Jul; 293(1):G104-11. PubMed ID: 17363465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota.
    Musch MW; Wang Y; Claud EC; Chang EB
    Dig Dis Sci; 2013 Mar; 58(3):668-77. PubMed ID: 23329012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal smooth muscle dysfunction develops postnatally in cystic fibrosis mice.
    De Lisle RC; Meldi L; Mueller R
    J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):689-94. PubMed ID: 22699839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the chloride channel activator lubiprostone for constipation in adults with cystic fibrosis: a case series.
    O'Brien CE; Anderson PJ; Stowe CD
    Ann Pharmacother; 2010 Mar; 44(3):577-81. PubMed ID: 20179256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia.
    Schiffhauer ES; Vij N; Kovbasnjuk O; Kang PW; Walker D; Lee S; Zeitlin PL
    Am J Physiol Lung Cell Mol Physiol; 2013 Mar; 304(5):L324-31. PubMed ID: 23316067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice.
    MacDonald KD; McKenzie KR; Henderson MJ; Hawkins CE; Vij N; Zeitlin PL
    Am J Physiol Lung Cell Mol Physiol; 2008 Nov; 295(5):L933-40. PubMed ID: 18805957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors.
    Hayashi S; Kurata N; Yamaguchi A; Amagase K; Takeuchi K
    J Pharmacol Exp Ther; 2014 Jun; 349(3):470-9. PubMed ID: 24713141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal phenotype of variable-weight cystic fibrosis knockout mice.
    Canale-Zambrano JC; Poffenberger MC; Cory SM; Humes DG; Haston CK
    Am J Physiol Gastrointest Liver Physiol; 2007 Jul; 293(1):G222-9. PubMed ID: 17615178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptor-4 genotype influences the survival of cystic fibrosis mice.
    Canale-Zambrano JC; Auger ML; Haston CK
    Am J Physiol Gastrointest Liver Physiol; 2010 Aug; 299(2):G381-90. PubMed ID: 20522639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype.
    Gustafsson JK; Ermund A; Ambort D; Johansson ME; Nilsson HE; Thorell K; Hebert H; Sjövall H; Hansson GC
    J Exp Med; 2012 Jul; 209(7):1263-72. PubMed ID: 22711878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential genetic modifiers of the cystic fibrosis intestinal inflammatory phenotype on mouse chromosomes 1, 9, and 10.
    Norkina O; De Lisle RC
    BMC Genet; 2005 May; 6():29. PubMed ID: 15921521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lubiprostone: clinical applications beyond constipation.
    Kapoor S
    World J Gastroenterol; 2009 Mar; 15(9):1147. PubMed ID: 19266613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.